Biotech

All Articles

After a challenging year, Exscientia folds up in to Recursion

.After a year defined by pipe hairstyles, the departure of its own CEO and unemployments, Exscientia...

Cullinan, after $25M bargain, return bispecific to Harbour

.Cullinan Therapeutics was actually excited sufficient with Port BioMed's bispecific immune reactor ...

A deeper take a look at Strong Biotech's Tough 15

.In this week's episode of "The Leading Pipe," our experts are actually diving into Fierce Biotech's...

Lilly encounters period 2 failing of tau-targeting med

.The confetti is still soaring coming from Eli Lilly's party commemorating the commendation of Alzhe...

Biogen CMO Maha Radhakrishnan signs up with Sofinnova-- Chutes &amp Ladders

.Invite to today's Chutes &amp Ladders, our summary of considerable management hirings, shootings an...

Lykos will certainly ask FDA to reassess its own choice observing being rejected of MDMA treatment for trauma

.Observing a bad revealing for Lykos Therapeutics' MDMA prospect for trauma at a latest FDA advising...

AN 2 one-halfs roll call, ceases phase 3 trial after data disappoint

.AN2 Therapies is actually reviewing its company in action to uninspired midphase data, pledging to ...

Merck pays for $700M for bispecific, snooping autoimmune opening and odds to test Amgen in cancer

.Merck &amp Co. is actually paying for $700 million upfront to test Amgen in a blood cancer cells ma...

Gilead pays J&ampJ $320M to go out licensing deal for seladelpar

.Along With Gilead Sciences about to an FDA decision for its own liver illness medication seladelpar...

' All hands on deck' at Lilly as peers target obesity market

.CEO David Ricks may see the providers establishing tents at basecamp behind Eli Lilly in a try to g...